Literature DB >> 19811907

ONCOPOOL - a European database for 16,944 cases of breast cancer.

R W Blamey1, B Hornmark-Stenstam, G Ball, M Blichert-Toft, L Cataliotti, A Fourquet, J Gee, K Holli, R Jakesz, M Kerin, R Mansel, R Nicholson, T Pienkowski, S Pinder, M Sundquist, M van de Vijver, I Ellis.   

Abstract

ONCOPOOL is a retrospectively compiled database of primary operable invasive breast cancers treated in the 1990s in 10 European breast cancer Units. Sixteen thousand and nine hundred and forty four cases were entered, with tumours less than 5 cm diameter in women aged 70 or less (mean age 55). DATA: Data were date of birth, mode of diagnosis, pathology (size, lymph node status, grade, type, lympho-vascular invasion and hormone receptor) and therapies and outcome measures: first local, regional or distant recurrences, contralateral primary, date and cause of death. TUMOUR CHARACTERISTICS: Mean diameter 1.8 cm, 66% lymph node negative, 24% 1-3 lymph nodes involved and 10% had 4 or more involved. Grade 1, 29%; Grade 2, 41%; and Grade 3, 30%. Polynomial relationships were established between grade, stage and size. Seventy-five percent were oestrogen receptor (ER) positive. ER closely related to grade. OUTCOMES: Overall Survival was 89% at 5 years from diagnosis, 80% 10 years and 73% 15 years; Breast Cancer-Specific survivals were 91%, 84% and 79%. Survival strongly related to the Nottingham Prognostic Index (NPI). Cases detected at screening had 84% 10-year survival, those presenting symptomatically 76%. ER positive cases treated with adjuvant hormone therapy had a reduction in risk of death of 13% over those not receiving adjuvant therapy (p=0.000). ER negative cases treated with chemotherapy showed a risk reduction of 23% over those not receiving chemotherapy (p=0.000).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19811907     DOI: 10.1016/j.ejca.2009.09.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  22 in total

1.  The Establishment and Utility of a Free Online Database of Primary Bone Tumors.

Authors:  Hairong Xu; Robert P Seifert; Xiaohui Niu; Yuan Li; Marilyn M Bui
Journal:  Pathol Oncol Res       Date:  2015-09-16       Impact factor: 3.201

2.  Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

Authors:  Marcelo Sobral-Leite; Koen Van de Vijver; Magali Michaut; Rianne van der Linden; Gerrit K J Hooijer; Hugo M Horlings; Tesa M Severson; Anna Marie Mulligan; Nayana Weerasooriya; Joyce Sanders; Annuska M Glas; Diederik Wehkamp; Lorenza Mittempergher; Kelly Kersten; Ashley Cimino-Mathews; Dennis Peters; Erik Hooijberg; Annegien Broeks; Marc J van de Vijver; Rene Bernards; Irene L Andrulis; Marleen Kok; Karin E de Visser; Marjanka K Schmidt
Journal:  Oncoimmunology       Date:  2018-09-11       Impact factor: 8.110

3.  Adopting Guidelines into Clinical Practice: Implementation of Trastuzumab in the Adjuvant Treatment of Breast Cancer in Lower Saxony, Germany, in 2007.

Authors:  Clemens Liebrich; Günter Unger; Birgit Dlugosch; Stefan Hofmann; Karl U Petry
Journal:  Breast Care (Basel)       Date:  2011-01-31       Impact factor: 2.860

Review 4.  Novel applications of molecular imaging to guide breast cancer therapy.

Authors:  Christine E Edmonds; Sophia R O'Brien; David A Mankoff; Austin R Pantel
Journal:  Cancer Imaging       Date:  2022-06-21       Impact factor: 5.605

Review 5.  Breast cancer prognostic classification in the molecular era: the role of histological grade.

Authors:  Emad A Rakha; Jorge S Reis-Filho; Frederick Baehner; David J Dabbs; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Jocelyne Jacquemier; Sunil R Lakhani; José Palacios; Andrea L Richardson; Stuart J Schnitt; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Sunil Badve; Ian O Ellis
Journal:  Breast Cancer Res       Date:  2010-07-30       Impact factor: 6.466

Review 6.  Nodal status assessment in breast cancer: strategies of clinical grounds and quality of life implications.

Authors:  Paolo Orsaria; Dimitrios Varvaras; Gianluca Vanni; Giampiero Pagnani; Jacopo Scaggiante; Federico Frusone; Alessandra Vittoria Granai; Giuseppe Petrella; Oreste Claudio Buonomo
Journal:  Int J Breast Cancer       Date:  2014-02-11

7.  Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.

Authors:  Andrew R Green; Daniele Soria; Jacqueline Stephen; Desmond G Powe; Christopher C Nolan; Ian Kunkler; Jeremy Thomas; Gillian R Kerr; Wilma Jack; David Cameron; Tammy Piper; Graham R Ball; Jonathan M Garibaldi; Emad A Rakha; John Ms Bartlett; Ian O Ellis
Journal:  J Pathol Clin Res       Date:  2016-01-15

8.  Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.

Authors:  Anne Vincent-Salomon; Vanessa Benhamo; Eléonore Gravier; Guillem Rigaill; Nadège Gruel; Stéphane Robin; Yann de Rycke; Odette Mariani; Gaëlle Pierron; David Gentien; Fabien Reyal; Paul Cottu; Alain Fourquet; Roman Rouzier; Xavier Sastre-Garau; Olivier Delattre
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

9.  Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.

Authors:  SiMin He; MingWei Wang; ZhongYi Yang; JianPing Zhang; YongPing Zhang; JianMin Luo; YingJian Zhang
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  Cancer incidence in eastern Morocco: cancer patterns and incidence trends, 2005-2012.

Authors:  Manal Elidrissi Errahhali; Mounia Elidrissi Errahhali; Meryem Ouarzane; Redouane Boulouiz; Mohammed Bellaoui
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.